ESMO 2026: Immune Profiling and Biomarkers in Stage III NSCLC
In this MEDtalk from ESMO 2026, Elisabeth Müller, PhD, Researcher, Oslo University Hospital, Norway, discusses findings from the DART study, presented as a poster at the congress. The study explores how deep immunophenotyping of blood samples from patients with stage III non-small cell lung cancer (NSCLC) may help identify biomarkers of treatment response. Preliminary findings suggest associations between immune cell profiles, PD-L1 status, and potential treatment resistance.







